1. DavisonAJ (2002) Evolution of the herpesviruses. Vet Microbiol 86: 69–88.
2. ChangY, CesarmanE, PessinMS, LeeF, CulpepperJ, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865–1869.
3. SoulierJ, GrolletL, OksenhendlerE, CacoubP, Cazals-HatemD, et al. (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86: 1276–1280.
4. CesarmanE, ChangY, MoorePS, SaidJW, KnowlesDM (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332: 1186–1191.
5. AmbroziakJA, BlackbournDJ, HerndierBG, GlogauRG, GullettJH, et al. (1995) Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science 268: 582–583.
6. MesriEA, CesarmanE, ArvanitakisL, RafiiS, MooreMA, et al. (1996) Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J Exp Med 183: 2385–2390.
7. DittmerD, LagunoffM, RenneR, StaskusK, HaaseA, et al. (1998) A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol 72: 8309–8315.
8. SaridR, FloreO, BohenzkyRA, ChangY, MoorePS (1998) Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol 72: 1005–1012.
9. SamolsMA, HuJ, SkalskyRL, RenneR (2005) Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. J Virol 79: 9301–9305.
10. CaiX, LuS, ZhangZ, GonzalezCM, DamaniaB, et al. (2005) Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci U S A 102: 5570–5575.
11. GrundhoffA, SullivanCS, GanemD (2006) A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 12: 733–750.
12. PfefferS, SewerA, Lagos-QuintanaM, SheridanR, SanderC, et al. (2005) Identification of microRNAs of the herpesvirus family. Nat Methods 2: 269–276.
13. SullivanSG, HirschHH, FranceschiS, SteffenI, AmariEB, et al. (2010) Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study. AIDS 24: 2245–2252.
14. GaoSJ, KingsleyL, LiM, ZhengW, ParraviciniC, et al. (1996) KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 2: 925–928.
15. DialynaIA, GrahamD, RezaeeR, BlueCE, StavrianeasNG, et al. (2004) Anti-HHV-8/KSHV antibodies in infected individuals inhibit infection in vitro. AIDS 18: 1263–1270.
16. KimballLE, CasperC, KoelleDM, MorrowR, CoreyL, et al. (2004) Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis 189: 2016–2022.
17. LehrnbecherTL, FosterCB, ZhuS, VenzonD, SteinbergSM, et al. (2000) Variant genotypes of FcgammaRIIIA influence the development of Kaposi's sarcoma in HIV-infected men. Blood 95: 2386–2390.
18. MuramatsuM, KinoshitaK, FagarasanS, YamadaS, ShinkaiY, et al. (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553–563.
19. WablM, BurrowsPD, von GabainA, SteinbergC (1985) Hypermutation at the immunoglobulin heavy chain locus in a pre-B-cell line. Proc Natl Acad Sci U S A 82: 479–482.
20. de YebenesVG, RamiroAR (2006) Activation-induced deaminase: light and dark sides. Trends Mol Med 12: 432–439.
21. RamiroAR, JankovicM, EisenreichT, DifilippantonioS, Chen-KiangS, et al. (2004) AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118: 431–438.
22. ShenHM, PetersA, BaronB, ZhuX, StorbU (1998) Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280: 1750–1752.
23. PasqualucciL, MigliazzaA, FracchiollaN, WilliamC, NeriA, et al. (1998) BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A 95: 11816–11821.
24. ConticelloSG, ThomasCJ, Petersen-MahrtSK, NeubergerMS (2005) Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol 22: 367–377.
25. ChiuYL, GreeneWC (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 26: 317–353.
26. GourziP, LeonovaT, PapavasiliouFN (2006) A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus. Immunity 24: 779–786.
27. EpeldeguiM, ThapaDR, De la CruzJ, KitchenS, ZackJA, et al. (2010) CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One 5: e11448.
28. IshikawaC, NakachiS, SenbaM, SugaiM, MoriN (2011) Activation of AID by human T-cell leukemia virus Tax oncoprotein and the possible role of its constitutive expression in ATL genesis. Carcinogenesis 32: 110–119.
29. MachidaK, ChengKT, SungVM, ShimodairaS, LindsayKL, et al. (2004) Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A 101: 4262–4267.
30. MatsumotoY, MarusawaH, KinoshitaK, EndoY, KouT, et al. (2007) Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 13: 470–476.
31. MyoungJ, GanemD (2011) Infection of lymphoblastoid cell lines by Kaposi's sarcoma-associated herpesvirus: critical role of cell-associated virus. J Virol 85: 9767–9777.
32. MyoungJ, GanemD (2011) Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells. Virology 413: 1–11.
33. TranTH, NakataM, SuzukiK, BegumNA, ShinkuraR, et al. (2010) B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat Immunol 11: 148–154.
34. DedeogluF, HorwitzB, ChaudhuriJ, AltFW, GehaRS (2004) Induction of activation-induced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFkappaB. Int Immunol 16: 395–404.
35. ZhouC, SaxonA, ZhangK (2003) Human activation-induced cytidine deaminase is induced by IL-4 and negatively regulated by CD45: implication of CD45 as a Janus kinase phosphatase in antibody diversification. J Immunol 170: 1887–1893.
36. MattaH, ChaudharyPM (2004) Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci U S A 101: 9399–9404.
37. RauletDH (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781–790.
38. GasserS, OrsulicS, BrownEJ, RauletDH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186–1190.
39. NormanJM, MashibaM, McNamaraLA, Onafuwa-NugaA, Chiari-FortE, et al. (2011) The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol 12: 975–983.
40. Stern-GinossarN, MandelboimO (2009) An integrated view of the regulation of NKG2D ligands. Immunology 128: 1–6.
41. JostS, AltfeldM (2013) Control of human viral infections by natural killer cells. Annu Rev Immunol 31: 163–194.
42. EspinozaJL, TakamiA, YoshiokaK, NakataK, SatoT, et al. (2012) Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions. Haematologica 97: 1295–1303.
43. GiurisatoE, CellaM, TakaiT, KurosakiT, FengY, et al. (2007) Phosphatidylinositol 3-kinase activation is required to form the NKG2D immunological synapse. Mol Cell Biol 27: 8583–8599.
44. EpeldeguiM, HungYP, McQuayA, AmbinderRF, Martinez-MazaO (2007) Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. Mol Immunol 44: 934–942.
45. MillerG, HestonL, GroganE, GradovilleL, RigsbyM, et al. (1997) Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol 71: 314–324.
46. VermaSC, BajajBG, CaiQ, SiH, SeelhammerT, et al. (2006) Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus recruits uracil DNA glycosylase 2 at the terminal repeats and is important for latent persistence of the virus. J Virol 80: 11178–11190.
47. KavliB, SundheimO, AkbariM, OtterleiM, NilsenH, et al. (2002) hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup. J Biol Chem 277: 39926–39936.
48. NilsenH, RosewellI, RobinsP, SkjelbredCF, AndersenS, et al. (2000) Uracil-DNA glycosylase (UNG)-deficient mice reveal a primary role of the enzyme during DNA replication. Mol Cell 5: 1059–1065.
49. CoscoyL (2007) Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol 7: 391–401.
50. DorsettY, McBrideKM, JankovicM, GazumyanA, ThaiTH, et al. (2008) MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 28: 630–638.
51. TengG, HakimpourP, LandgrafP, RiceA, TuschlT, et al. (2008) MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 28: 621–629.
52. de YebenesVG, BelverL, PisanoDG, GonzalezS, VillasanteA, et al. (2008) miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med 205: 2199–2206.
53. BorchertGM, HoltonNW, LarsonED (2011) Repression of human activation induced cytidine deaminase by miR-93 and miR-155. BMC Cancer 11: 347.
54. YinQ, McBrideJ, FewellC, LaceyM, WangX, et al. (2008) MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J Virol 82: 5295–5306.
55. LinnstaedtSD, GottweinE, SkalskyRL, LuftigMA, CullenBR (2010) Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol 84: 11670–11678.
56. RahadianiN, TakakuwaT, TresnasariK, MoriiE, AozasaK (2008) Latent membrane protein-1 of Epstein-Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines. Biochem Biophys Res Commun 377: 579–583.
57. GottweinE, MukherjeeN, SachseC, FrenzelC, MajorosWH, et al. (2007) A viral microRNA functions as an orthologue of cellular miR-155. Nature 450: 1096–1099.
58. SkalskyRL, SamolsMA, PlaisanceKB, BossIW, RivaA, et al. (2007) Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol 81: 12836–12845.
59. BartelDP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.
60. GottweinE, CorcoranDL, MukherjeeN, SkalskyRL, HafnerM, et al. (2011) Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe 10: 515–526.
61. LeiX, BaiZ, YeF, XieJ, KimCG, et al. (2010) Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat Cell Biol 12: 193–199.
62. ZhouFC, ZhangYJ, DengJH, WangXP, PanHY, et al. (2002) Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol 76: 6185–6196.
63. EndoY, MarusawaH, KinoshitaK, MorisawaT, SakuraiT, et al. (2007) Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 26: 5587–5595.
64. SirianniMC, VincenziL, TopinoS, GiovannettiA, MazzettaF, et al. (2002) NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 32: 2711–2720.
65. MatthewsNC, GoodierMR, RobeyRC, BowerM, GotchFM (2011) Killing of Kaposi's sarcoma-associated herpesvirus-infected fibroblasts during latent infection by activated natural killer cells. Eur J Immunol 41: 1958–1968.
66. MadridAS, GanemD (2012) Kaposi's sarcoma-associated herpesvirus ORF54/dUTPase downregulates a ligand for the NK activating receptor NKp44. J Virol 86: 8693–8704.
67. ThomasM, BonameJM, FieldS, NejentsevS, SalioM, et al. (2008) Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A 105: 1656–1661.
68. NachmaniD, Stern-GinossarN, SaridR, MandelboimO (2009) Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 5: 376–385.
69. WuX, GeraldesP, PlattJL, CascalhoM (2005) The double-edged sword of activation-induced cytidine deaminase. J Immunol 174: 934–941.
70. LiangG, KitamuraK, WangZ, LiuG, ChowdhuryS, et al. (2013) RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase. Proc Natl Acad Sci U S A 110: 2246–2251.
71. AriasC, WalshD, HarbellJ, WilsonAC, MohrI (2009) Activation of host translational control pathways by a viral developmental switch. PLoS Pathog 5: e1000334.
72. Lukac DM, Yuan Y (2007) Reactivation and lytic replication of KSHV. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B et al.., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge.
73. BransteitterR, PhamP, ScharffMD, GoodmanMF (2003) Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci U S A 100: 4102–4107.
74. WilsonSJ, TsaoEH, WebbBL, YeH, Dalton-GriffinL, et al. (2007) X box binding protein XBP-1s transactivates the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency. J Virol 81: 13578–13586.
75. SiegelAM, RangaswamyUS, NapierRJ, SpeckSH (2010) Blimp-1-dependent plasma cell differentiation is required for efficient maintenance of murine gammaherpesvirus latency and antiviral antibody responses. J Virol 84: 674–685.
76. TobollikS, MeyerL, BuettnerM, KlemmerS, KempkesB, et al. (2006) Epstein-Barr virus nuclear antigen 2 inhibits AID expression during EBV-driven B-cell growth. Blood 108: 3859–3864.
77. SernandezIV, de YebenesVG, DorsettY, RamiroAR (2008) Haploinsufficiency of activation-induced deaminase for antibody diversification and chromosome translocations both in vitro and in vivo. PLoS One 3: e3927.
78. ZhangW, BardwellPD, WooCJ, PoltoratskyV, ScharffMD, et al. (2001) Clonal instability of V region hypermutation in the Ramos Burkitt's lymphoma cell line. Int Immunol 13: 1175–1184.
79. LuCC, LiZ, ChuCY, FengJ, FengJ, et al. (2010) MicroRNAs encoded by Kaposi's sarcoma-associated herpesvirus regulate viral life cycle. EMBO Rep 11: 784–790.
80. LuF, StedmanW, YousefM, RenneR, LiebermanPM (2010) Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J Virol 84: 2697–2706.
81. BellareP, GanemD (2009) Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe 6: 570–575.
82. LinX, LiangD, HeZ, DengQ, RobertsonES, et al. (2011) miR-K12-7-5p encoded by Kaposi's sarcoma-associated herpesvirus stabilizes the latent state by targeting viral ORF50/RTA. PLoS One 6: e16224.
83. ZiegelbauerJM, SullivanCS, GanemD (2009) Tandem array-based expression screens identify host mRNA targets of virus-encoded microRNAs. Nat Genet 41: 130–134.
84. OkazakiIM, KotaniA, HonjoT (2007) Role of AID in tumorigenesis. Adv Immunol 94: 245–273.
85. SilvaJM, LiMZ, ChangK, GeW, GoldingMC, et al. (2005) Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37: 1281–1288.